Biotech Values

[DewDiligence]

It’s a little early to be writing off all-oral HCV regimens, IMO. In patients who had a null response to SoC in the first-line setting—the group BMY tested in the abstract you posted—three DAA’s rather than two will likely be needed to prevent viral breakthrough/rebound. The obvious addition to a cocktail consisting of a PI and an NS5A is a nuke.